Clinical trials: Pharynx Cancer
Oropharyngeal Cancer
Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers
This study is to determine whether a mathematical model can be used to choose a radiation delivery method to improve the rate of a rapid response.
- Trial name
- NCT03656133
- Testing
- Radiotherapy fractionation
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Dysphagia, Oral Pharyngeal Cancer
Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy
Patients with head and neck cancer treated with chemoradiation, often develop a treatment associated dysphagia. The common complaint is foods sticking in the pharynx.
- Trial name
- NCT02564887
- Testing
- Iowa Oral Performance Instrument
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jonas Johnson
HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
Background: For some cancers associated with human papillomavirus (HPV), standard treatments are not helpful. Researchers want to see if a vaccine for HPV combined with a drug called M7824 (MSB0011359C) has a better effect on…
- Conditions
- HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer, Oropharyngeal Cancer
- Trial name
- NCT04432597
- Testing
- PRGN-2009, M7824, EKG
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Squamous Cell, Oral Cancer
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Participants in this study have a type of cancer called squamous cell carcinoma of the head and neck (SCCHN). Their SCCHN has spread around the area where the cancer first started. This is called locally-advanced SCCHN.
- Conditions
- Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer
- Trial name
- NCT03174275
- Testing
- Durvalumab, Carboplatin, Nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
This phase II/III trial studies how well radiation therapy works with durvalumab or cetuximab in treating patients with head and neck cancer that has spread to a local and/or regional area of the body who cannot take cisplatin.
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT03258554
- Testing
- Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy
- Where
- 256 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- National Cancer Institute (NCI)
Mouth Neoplasms, Oropharyngeal Neoplasms
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
This is an imaging protocol only, not a therapeutic study. The primary goal of the proposed study is to examine the utility of a new imaging study, Positron Emission Tomography with F-18 Fluorothymidine (FLT PET), in the early…
- Conditions
- Mouth Neoplasms, Oropharyngeal Neoplasms, Laryngeal Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT00721799
- Testing
- 18F-Fluorothymidine PET scan
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Iowa
Human Papilloma Virus, Cervical Cancer
M7824 in Subjects With HPV Associated Malignancies
Background: In the United States, each year there are more than 30,000 cases of human papillomavirus (HPV) associated cancers. Some of these cancers are often incurable and are not improved by standard therapies.
- Conditions
- Human Papilloma Virus, Cervical Cancer, Oropharyngeal Cancer, Anal Cancer
- Trial name
- NCT03427411
- Testing
- M7824
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement (recurrent) and/or has spread to other parts of the body (metastatic).
- Conditions
- Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharynx Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7
- Trial name
- NCT02339558
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- 19 sites in United States, China and 1 more
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
This phase II trial investigates how well sodium thiosulfate works in preventing ototoxicity (hearing loss/damage) in patients with squamous cell cancer of the head and neck that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT04541355
- Testing
- Cisplatin, Hearing Handicap Inventory for Adults - Screening, Radiation Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Hyunseok Kang, MD
Nasopharyngeal Cancer
Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
The purpose of this study is to determine whether avelumab, an investigational antibody against programmed death-ligand (PD-L1), has an effect on recurrent nasopharyngeal cancer.
- Trial name
- NCT02875613
- Testing
- Avelumab
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Assuntina Sacco, M.D.
Head Cancer, Neck Cancer
Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)
The overall goal of this study is to examine the effect of a single dose of TENS on mucositis pain and function secondary to head and neck radiation therapies.
- Conditions
- Head Cancer, Neck Cancer, Pain
- Trial name
- NCT01194466
- Testing
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Jennifer E. Lee
Head and Neck Cancer, Dysphagia
Clinical Impact of Respiratory-Swallow Training on Refractory Dysphagia in Oropharyngeal Head and Neck Cancer
Veterans following treatment of head and neck cancer can be left with lasting swallowing impairment that may require diet alterations, need for feeding tubes, and risk of pneumonia.
- Trial name
- NCT03377270
- Testing
- Respiratory Swallow Training
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- VA Office of Research and Development
Recurrent Oropharynx Carcinoma
Changes to Function and Quality of Life and Patient Experience for Patients Undergoing Treatments for Recurrent Oropharyngeal Cancer
The purpose of this research project is to measure changes in communication, swallowing and quality of life and individual patient priorities which may happen over time in patients with a diagnosis of recurrent head and neck…
- Trial name
- FUNQOLR (NCT04952922)
- Testing
- Treatment for recurrent oropharyngeal cancer (curative/ palliative)
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Head and Neck Cancer, Mucositis Oral
GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
GM-CSF may protect normal cells from the side effects, such as mucositis, of radiation therapy and may help damaged tissue heal faster after radiation therapy.
- Conditions
- Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
- Trial name
- NCT00293462
- Testing
- sargramostim, oral salt and soda mouthwash
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Marilyn Dodd
Bladder Cancer, Cervical Cancer
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00790569
- Testing
- nicotine, varenicline
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Butler Hospital
Head and Neck Cancer
Image-Guided Adaptive Radiotherapy for in Detecting Tumors During Treatment in Patients With Head and Neck Cancer
This clinical trial studies image-guided adaptive radiotherapy in detecting tumors during treatment in patients with head and neck cancer.
- Trial name
- NCT01843673
- Testing
- computed tomography, cone-beam computed tomography, radiography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Virginia Commonwealth University
Advanced Cancer
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with…
- Trial name
- NCT03674567
- Testing
- FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
- Where
- 35 sites in United States, Australia and 4 more
- Volunteers
- 323 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Wilms Tumor, Fibrosarcoma
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.
- Conditions
- Wilms Tumor, Fibrosarcoma, Carcinoma, Round Cell, Nasopharyngeal Cancer
- Trial name
- NCT00141765
- Testing
- Myeloablative Chemotherapy, Stem Cell Rescue
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Head and Neck Cancer
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00833261
- Testing
- cetuximab, cisplatin, intensity-modulated radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Texas Southwestern Medical Center
Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
This study will evaluate the safety and efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with…
- Conditions
- Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma
- Trial name
- NCT05166577
- Testing
- Nanatinostat, Valganciclovir, Pembrolizumab
- Where
- 13 sites in United States, Australia and 6 more
- Volunteers
- 26 people
- Sponsor
- Viracta Therapeutics, Inc.